Information Theory Framework TCRi, Linking T-cell Genotype and Cell State, Opens New Horizons for Predicting Immunotherapy Response
Background
T-cells, the key commanders of the immune system, recognize antigens and form unique cell states through T-cell receptor (TCR) sequences present on their surface. Quantifying the correlation between the genotype (the receptor sequence information of individual T-cells) and the phenotype (represented by gene expression patterns) has been a long-standing challenge. Despite significant advancements in single-cell transcriptome analysis and TCR repertoire sequencing technologies, it has been difficult to link the random diversity of sequences and complex cell differentiation pathways with a single computational formula.
Existing studies have been limited to methods such as counting the proliferation frequency of specific clones or simply comparing the expression levels of known differentiation markers. These static analyses fail to explain the fundamental causal role of receptor sequences in determining cell state diversity. Because the reasons for the drastic variation in T-cell responses among patients undergoing anticancer immunotherapy could not be elucidated at the cellular sequence level, the discovery of effective biomarkers has also reached its limits.
Key Findings
Researchers have constructed TCRi, a computational framework that integrates the concept of mutual information (MI) from information theory into immunogenomics. TCRi precisely calculates the shared non-linear information between the receptor sequence variations of individual T-cells and their transcriptome profiles. It is an algorithm that directly measures, in a non-parametric manner, how much the genotypic sequence reduces the uncertainty of the cellular phenotype.
Analyzing integrated datasets of single-cell RNA sequencing (scRNA-seq) and single-cell TCR sequencing (scTCR-seq) with TCRi revealed that the mutual information between T-cell receptor sequences and cell states is a key indicator determining the response to immune checkpoint inhibitor therapy. Patient groups exhibiting high mutual information showed significant correlations with long-term survival rates and tumor shrinkage rates following immunotherapy. Compared to existing indicators such as clonal expansion or simple cell differentiation indices, the mutual information index calculated by TCRi demonstrated clear discriminative power in predicting patient treatment prognosis.
Significance and Outlook
This study represents a breakthrough in resolving the genotype-phenotype network of immune cells—a longstanding challenge in complex systems biology—by reducing it to mathematical information theory. By quantifying the deterministic impact of T-cell sequences themselves on cell fate, it has established a computational framework applicable not only to immuno-oncology but also to research in autoimmune diseases and infectious diseases. It lays the foundation for advancing algorithms capable of gauging the immune response potential of a cell using only the receptor sequence.
For actual clinical entry, further validation work in various cancer types and large-scale patient cohorts must follow. Challenges remain in correcting errors in mutual information calculation due to sequencing depth and sample collection timing, and in establishing a standardized pipeline that can be immediately integrated into clinical practice.
Nature Genetics, Published online: 05 November 2026; doi:10.1038/s41588-026-02781-x T cells provide a unique setting for quantification of the relationship between genotype and phenotype. The authors introduce TCRi, an information-theoretic framework for this, and find mutual information to be a robust determinant of immunotherapeutic response.
The TCRi framework serves as a next-generation precision diagnostic algorithm for the early screening of responsiveness to anticancer immunotherapy. By analyzing T cells in a patient’s blood or tumor tissue at the single-cell level to derive mutual information values prior to prescribing immune checkpoint inhibitors, it enables the pre-identification of drug-refractory patients, thereby reducing unnecessary treatment costs and immune-related adverse events.
It can also be utilized as a critical quality indicator in the development process of cell therapies. When manufacturing patient-specific CAR-T or TCR-T therapies, it is possible to design a pipeline that dramatically enhances the in vivo persistence and anticancer activity of the therapeutic agent by selecting the optimal T-cell clone state capable of maximizing therapeutic efficacy using mutual information metrics.